vaccines-gynecologic-oncology-2018-posters

Page 85

Journal of Clinical Immunology and Allergy

ISSN: 2471-304X

E u r o p e a n C o n g r e s s o n

Vaccines & Vaccination

and Gynecologic Oncology

Vaccines & Vaccination and Gynecologic Oncology 2018

O c t o b e r 2 6 - 2 7 , 2 0 1 8

B u d a p e s t , H u n g a r y

eisseria meningitidis

is a Gram-negative bacterium and causative agent of life-threatening meningococcal disease in humans

(meningitis and septicaemia). The conventional approach of capsular polysaccharide (CPS) usage as a platform for meningococ-

cal vaccines’ development has been very effective with serogroups A, C, W135 and Y, but limited effect with serogroup B (MenB) due

to antigenic similarity of its CPS with human antigen. A well-studied virus-like particle (VLP), Hepatitis B core antigen (HBcAg) was

used as a scaffold to incorporate meningococcal surface antigens. The VLP-antigen fusion proteins were expressed, purified and char-

acterized by SDS-PAGE analysis, circular dichroism and transmission electron microscopy. Uptake of the VLP-antigen fusion proteins

by THP-1-derived dendritic cells and macrophages was carried out

in vitro

. Intracellular co-localization and upregulation of surface

markers were assessed by cell culture, ImageStream and FACS analysis. The VLP-antigen proteins were shown to be taken up by clath-

rin-mediated endocytosis and macropinocytosis and co-localized in lysosomes. They also significantly stimulate higher upregulation

of HLA-DR, CD80, CD206 and CD209 on macrophages compared to the antigen alone.

Virus like particles as a scaffold for

meningococcal vaccine development

Murtala Jibril, Emil Carlsson, Sebastian Aston-Deaville,

Jeremy Derrick

University of Manchester, UK

Journal of Clinical Immunology and Allergy, Volume: 4

DOI: 10.21767/2471-304X-C2-006

Euro Vaccines 2018